Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2827415 | 0.85 | GRM5 (0.44) | GRM5CA12CA1CA2CA9 | |
| SCHEMBL2068502 | 0.79 | PPARD (0.53) | FFAR1 | |
| SCHEMBL2068483 | 0.76 | MMP2 (0.41) | GRM5CA12CA1CA2CA9 | |
| SCHEMBL2820978 | 0.75 | GRM5 (0.44) | GRM5 | |
| SCHEMBL6132140 | 0.72 | GRM5 (0.66) | GRM5CA12CA1CA2CA9 | |
| SCHEMBL30707880 | 0.72 | GRM5 (0.66) | GRM5CA12CA1CA2CA9 | |
| SCHEMBL2825829 | 0.69 | GRM5 (0.43) | GRM5HAO1 | |
| SCHEMBL4267103 | 0.68 | CA12 (0.63) | GRM5CA12CA1CA2CA9 | |
| SCHEMBL13335288 | 0.67 | CA12 (0.62) | GRM5CA12CA1CA2CA9 | |
| SCHEMBL2825595 | 0.67 | P4HB (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745003-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-27 | — | — | EP | claimed |